ProfileGDS5678 / 1424368_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 93% 94% 94% 93% 95% 94% 94% 94% 93% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8983293
GSM967853U87-EV human glioblastoma xenograft - Control 27.9808593
GSM967854U87-EV human glioblastoma xenograft - Control 37.9762893
GSM967855U87-EV human glioblastoma xenograft - Control 48.3695394
GSM967856U87-EV human glioblastoma xenograft - Control 58.2386294
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6719393
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.1295895
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0667394
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9592494
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0513294
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7939893
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9215193
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9487793
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9506493